

# VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100**

## Overview

2024/05/03 22:30:01	
<b>Price</b>	401.08 USD
<b>Difference</b>	<span style="color: green;">▲</span> 0.23% (0.92)

General attributes	
ISIN	US92532F1003
Symbol	VRTX
Exchange	Nasdaq
Currency	USD
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	96,555 EUR
Benchmark	S&P 500

Market data	
Bid (Bid size)	400.68 USD (400)
Ask (Ask size)	408.70 USD (100)
Open	401.50 USD
High	405.665 USD
Low	397.59 USD
Close (prev. day)	400.16 USD
VWAP	401.131123 USD
Volume (pcs)	1,064,066
Trading volume	426,788,308.18
Number of trades	28,095
Last size	-

Futures and Options	
Related Futures	-
Related Options	-

PDF Downloads	
Company report: VERTEX PHARMACEUTICALS INC.	<a href="#">Download</a>



Information about previous performance does not guarantee future performance.  
Source: FactSet

### Recent research

on instrument	on sector	on market	
Date		Headline	Download
2024/04/26		Global Equity Ratings	<a href="#">Download</a>
2024/04/03		Global Equity Ratings	<a href="#">Download</a>
2024/03/13		Global Equity Ratings	<a href="#">Download</a>
2024/02/22		Global Equity Ratings	<a href="#">Download</a>
2024/02/14		Global Equity Ratings	<a href="#">Download</a>

## Details

2024/05/03 22:30:01

**Price**  
401.08 USD

**Difference** ▲ 0.23% (0.92)

### General attributes

ISIN	US92532F1003
Symbol	VRTX
Exchange	Nasdaq
Currency	USD
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	96,555 EUR
Benchmark	S&P 500

### Market data

Bid (Bid size)	400.68 USD (400)
Ask (Ask size)	408.70 USD (100)
Open	401.50 USD
High	405.665 USD
Low	397.59 USD
Close (prev. day)	400.16 USD
VWAP	401.131123 USD
Volume (pcs)	1,064,066
Trading volume	426,788,308.18
Number of trades	28,095
Last size	-

### Performance and Risk

	6m	1Y	3Y
Perf (%)	+6.61%	+15.80%	+84.02%
Perf (abs.)	+24.88	+54.72	+183.13
Beta	0.66	0.64	0.60
Volatility	26.97	23.11	27.15

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

### Price data

Ø price 5 days   Ø volume 5 days (pcs.)	398.48 USD (1,140,860)
Ø price 30 days   Ø volume 30 days (pcs.)	403.45 USD (969,418)
Ø price 100 days   Ø volume 100 days (pcs.)	413.88 USD (1,294,106)
Ø price 250 days   Ø volume 250 days (pcs.)	376.18 USD (1,222,677)
YTD High   date	448.40 USD (2024/01/30)
YTD Low   date	391.01 USD (2024/04/18)
52 Weeks High   date	448.40 USD (2024/01/30)
52 Weeks Low   date	320.01 USD (2023/06/01)

### All listings for VERTEX PHARMACEUTICALS INC.

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/05/03	17:35	370.50 EUR	0.02	6
Vienna Stock Exchange	2024/05/03	17:32	371.20 EUR	0.01	4
Tradegate	2024/05/03	22:26	372.60 EUR	0.12	23
Stuttgart	2024/05/03	16:42	369.70 EUR	0.00	9
Nasdaq	2024/	22:30	401.08 USD	426.79	28,095

	05/03					
Munich	2024/ 05/03	08:00	373.90 EUR	0.00		1
London Stock Exchange	2024/ 05/01	16:15	395.45 USD	0.14		1
Hanover	2024/ 05/03	08:02	373.85 EUR	0.00		3
Hamburg	2024/ 05/03	08:00	373.85 EUR	0.00		3
Frankfurt	2024/ 05/03	08:06	372.85 EUR	0.00		2
Euronext Milan MTF Trading After Hours	2024/ 04/29	20:01	371.75 EUR	0.00		1
Euronext Milan MTF Global Equity Market	2024/ 05/03	17:44	370.50 EUR	0.00		3
Duesseldorf	2024/ 05/03	19:30	372.75 EUR	0.00		7
Berlin	2024/ 05/03	08:08	373.85 EUR	0.00		2

## Company profile

### Company Logo



### Contact Details

VERTEX PHARMACEUTICALS INC.

--

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: [mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

### PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC.



### Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

### Members of Management Board

Jeffrey Leiden Chairman of Board of Directors

Alan Garber Member of Board of Directors

Sangeeta Bhatia Member of Board of Directors

Bruce Sachs Member of Board of Directors

Diana McKenzie Member of Board of Directors

Lloyd Carney Member of Board of Directors

Michel Lagarde Member of Board of Directors

Nancy Thornberry Member of Board of Directors

Suketu Upadhyay Member of Board of Directors

Terrence Kearney Member of Board of Directors

Reshma Kewalramani Chairman of Managing Board

David Altshuler Member of Executive Committee

Amit K. Sachdev Member of Executive Committee

Bastiano Sanna Member of Executive Committee

Carmen Bozic Member of Executive Committee

Charles F. Wagner Member of Executive Committee

E. Morrey Atkinson Member of Executive Committee

Jonathan Biller Member of Executive Committee

Nia Tatsis Member of Executive Committee

Stuart A. Arbuckle Member of Executive Committee

